Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/QLT Visudyne adds indications

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Verteporfin receives clearance for two new indications Aug. 22 - use in pathologic myopia and presumed ocular histoplasmosis. The new label also adds 24-month data on treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, as well as updated information in the "adverse reactions" section. Visudyne sales in 2000 reached $100 mil. worldwide. QLT is projecting sales of $225 mil. to $250 mil. this year, assisted by the expanded indications. Novartis and QLT are testing other indications including AMD dominated by occult CNV, minimally classic CNV secondary to AMD, and non-melanoma skin cancer
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel